Discordant empirical antibiotic therapy of Pseudomonas aeruginosa infection


African Journal of Clinical and Experimental Microbiology. ISSN 1595-689X

Copyright AJCEM 2024: https://dx.doi.org/10.4314/ajcem.v25i1.11

Original Article

Discordant rate between empirical antibiotics administered and antimicrobial susceptibility in infections caused by Pseudomonas aeruginosa in a tertiary hospital in Nigeria

*Igunma, J. A., and 1,2Lofor, P. V. O.

1Department of Medical Microbiology, University of Benin Teaching Hospital, Benin City, Edo State, Nigeria
2Department of Medical Microbiology, University of Benin/University of Benin Teaching Hospital, Benin City, Edo State, Nigeria

*Correspondence to: docigunma@gmail.com; +2348032690163

Abstract:

Background Early initiation of appropriate antibiotics is key to the effective management of severe bacterial infections. The initiation of targeted antibiotic therapy is possible only when the causative organism is isolated. As a result, antibiotics are usually administered on an empirical basis guided by the clinical presentation, local antibiotic guidelines and other relevant histories. Generally, empirical antibiotics differ for both community- and hospital-acquired infections (HAIs), as a result of which common HAI pathogens such as Pseudomonas aeruginosa should be deliberately targeted, because most routine antibiotics are ineffective against them.

Methodology: This was a retrospective cross-sectional study involving the review of the clinical consults sent to clinical microbiologists at the University of Benin Teaching Hospital (UBTH) between January and December 2022. The consults were analyzed for the initial diagnosis, reasons for the invitation and empirical antibiotics administered. Other relevant informations were obtained from the laboratory records. Susceptibility profiles of P. aeruginosa isolates were compared with the empirical antibiotics administered. Discordant empirical antibiotic therapy was defined as the administration of antibiotic regimen with no anti-pseudomonal activity.

Results: Of the 256 consults received over the period of study, P. aeruginosa was isolated from 57 (22.3%) patients as pathogens. Out of this, 24.6% (n=14) received at least one anti-pseudomonas antibiotic, which puts the total discordant rate at 75.4%. Metronidazole (22.7%) and ceftriaxone-sulbactam (Tandak) (21.5%) were the most commonly prescribed empirical antibiotics. The most common reason for consultation was a diagnosis of sepsis at 40.2% followed by pan-resistant isolates at 34.8%.

Conclusion: Although the commonly prescribed antibiotics in our setting are broad spectrum, they lack coverage for P. aeruginosa which is one of the most common pathogens implicated in HAIs.

Keywords: Pseudomonas aeruginosa, discordant antibiotics, empiric antibiotics

Received Nov 6, 2023; Revised Dec 18, 2023; Accepted Dec 19, 2023

Copyright 2024 AJCEM Open Access. This article is licensed and distributed under the terms of the Creative Commons Attribution 4.0 International License “a rel="license" href="http://creativecommons.org/licenses/by/4.0/” which permits unrestricted use, distribution and reproduction in any medium, provided credit is given to the original author(s) and the source. Editor-in-Chief: Prof. S. S. Taiwo

Taux de discordance entre les antibiotiques empiriques administrés et la sensibilité aux antimicrobiens dans les infections causées par Pseudomonas aeruginosa dans un hôpital tertiaire au Nigeria

*Igunma, J. A., et 1,2Lofor, P. V. O.

1Département de Microbiologie Médicale, Hôpital Universitaire de l’Université du Bénin, Bénin Ville, État d’Edo, Nigéria
2Département de Microbiologie Médicale, Université du Bénin/Hôpital Universitaire de l’Université du Bénin, Bénin Ville, État d’Edo, Nigéria

*Correspondance à: docigunma@gmail.com; +2348032690163

Résumé:

Contexte: L’instauration précoce d’un traitement antibiotique approprié est essentielle à la prise en charge efficace des infections bactériennes graves. L’instauration d’une antibiothérapie ciblée n’est possible que lorsque l’organisme causal est isolé. En conséquence, les antibiotiques sont généralement administrés sur une base empirique, guidée par la présentation clinique, les directives locales en matière d’antibiotiques et d’autres antécédents pertinents. En général, les antibiotiques empiriques diffèrent à la fois pour les infections nosocomiales et celles nosocomiales (IAS), de sorte que les agents pathogènes courants des IAS, tels que Pseudomonas aeruginosa, doivent être délibérément ciblés, car la plupart des antibiotiques courants sont
Discordant empirical antibiotic therapy of Pseudomonas aeruginosa infection

Introduction:
Early initiation of appropriate antibiotics is key to the effective management of bacterial infections. However, initiation of targeted antibiotic therapy is possible only when the causative organism is isolated and subsequently, antimicrobial susceptibility testing performed. As a result, antibiotics are often given on an empirical basis guided by the clinical presentation, other relevant clinical histories and local antibiotics guidelines, as complete culture results usually take 24 to 48 hours. It has been shown that delay and or administration of inadequate antibiotics for infections in the critically ill is often associated with adverse outcomes including higher morbidity and mortality as well as extended length of hospital stay.

Empirical therapy is simply defined as the initial antibiotic regimen selected in the absence of definitive microbiological pathogen identification and susceptibility testing. On the hand, targeted or definitive therapy is the antibiotic regimen selected after pathogen identification and susceptibility testing is completed. The common approach to prescribing on empirical basis include; the use of broad-spectrum antimicrobial agents as initial therapy, which could be achieved by mono-therapy or a combination of antimicrobial agents, with the aim of covering multiple possible organisms commonly associated with the specific clinical syndrome including Gram-positive, Gram-negative, anaerobes as well as atypical bacteria.

Worthy of note is that empirical choices differ for both community and hospital-acquired infections. For example, adults with community-acquired pneumonia should be started on either a respiratory fluoroquinolone such as levofloxacin or combination of a beta-lactam (amoxicillin/amoxicillin-clavulanic acid) and a macrolide. However, in hospital-acquired pneumonia, antibiotics regimen for empirical coverage should include antipseudomonals such as piperacillin/tazobactam, cefepime, levofoxacin, imipenem or meropenem.

In the case of hospital-acquired infections (HAI)s, which are frequently associated with the presence of invasive devices and procedures that compromises the normal barriers to infection such as intravascular catheter-associated bacteraemia, ventilator-associated pneumonia, and catheter-associated urinary tract infections (CAUTI), the offending pathogens are frequently multi-drug-resistant organisms, which is true for both Gram-positive (e. g. MRSA) and Gram-negative (e. g. Pseudomonas aeruginosa) bacteria. The sources of these resistance phenotypes have been linked to the hospital environment which often serves as a reservoir for these pathogens, primarily due to selection pressure from frequent antimicrobial use in the hospital.

Therefore, to select empirical antimicrobial therapy for HAI, the following should be considered; (i) the site of infection and the most likely organisms colonizing that site, for example, central-line associated blood stream infection frequently results from skin flora such as staphylococci inoculated into the bloodstream by the process of catheterization, (ii) prior knowledge of bacteria known to colonize a given patient e.g. screening by the use of nasal swab and faecal screening for the carriage of carbapenem-resistant Gram-negative bacteria pathogens, which is currently been conducted routinely by many hospitals before admitting patients to the intensive care unit or before highly invasive surgeries, and (iii) the local bacterial resistance profile or antibiograms.

Initial antibiotic therapy in critically ill does not only need to be timely, but should be appropriate. Appropriateness can be defined as antimicrobial coverage that provides adequate in vitro activity against all likely pathogens at the clinical infection site of interest. When considering targeted therapy, appropriateness is defined as antimicrobials with in vitro activity against the isolated pathogen, or appropriate for the underlying clinical syndrome even if no pathogen was isolated.

Mots clés: Pseudomonas aeruginosa, antibiotiques discordants, antibiotiques empiriques

Méthodologie: Il s’agit d’une étude rétrospective transversale portant sur la revue des consultations cliniques adressées aux microbiologistes cliniciens de l’Hôpital Universitaire du Bénin (UBTH) entre janvier et décembre 2022. Les consultations ont été analysées pour le diagnostic initial, les raisons de l’invitation et antibiotiques empiriques administrés. D’autres informations pertinentes ont été obtenues à partir des dossiers de laboratoire. Les profils de sensibilité des isolats de P. aeruginosa ont été comparés à ceux des antibiotiques empiriques administrés. Une antibithérapie empirique discordante a été définie comme l’administration d’un régime antibiotique sans activité anti-pseudomonas.

Résultats: Parmi les 256 consultations reçues au cours de la période d’étude, P. aeruginosa a été isolé comme pathogène chez 57 (22,3%) patients. Sur ce total, 24,6% (n=14) ont reçu au moins un antibiotique anti-pseudomonas, ce qui porte le taux discordant total à 75,4%. Le métronidazole (22,7%) et la ceftriaxone-sulbactam (Tandak) (21,5%) étaient les antibiotiques empiriques les plus couramment prescrits. Le motif de consultation le plus fréquent était un diagnostic de sepsis à 40,2% suivi d’isolats pan-pseudomonas, ce qui porte le taux discordant total à 75,4%. Le métronidazole (22,7%) et la ceftriaxone-sulbactam (Tandak) (21,5%) étaient les antibiotiques empiriques les plus couramment prescrits. Le motif de consultation le plus fréquent était un diagnostic de sepsis à 40,2% suivi d’isolats pan-pseudomonas, ce qui porte le taux discordant total à 75,4%. Le métronidazole (22,7%) et la ceftriaxone-sulbactam (Tandak) (21,5%) étaient les antibiotiques empiriques les plus couramment prescrits. Le motif de consultation le plus fréquent était un diagnostic de sepsis à 40,2% suivi d’isolats pan-pseudomonas, ce qui porte le taux discordant total à 75,4%.

Conclusion: Bien que les antibiotiques couramment prescrits dans notre contexte soient à large spectre, ils manquent de couverture pour P. aeruginosa qui est l’un des plus courants agents pathogènes courants impliqués dans les IAS.

Mots clés: Pseudomonas aeruginosa, antibiotiques discordants, antibiotiques empiriques
Empirical antibiotic therapy is considered discordant if the bloodstream isolate does not display in vitro susceptibility to any systemic antibiotic administered on the day of blood culture sampling. Such a scenario includes meningitis and antibiotic regimen that crosses the blood-brain barrier (8).

Common predictors of discordant empirical antibiotic therapy (DEAT) include but are not limited to high prevalence of antibiotic-resistant phenotypes in the setting, infections due to non-glucose fermenting Gram-negative organisms (Acinetobacter baumannii and P. aeruginosa) and presence of Enterococcus spp and infection due to resistant phenotypes (9). Among Gram-negative infections, P. aeruginosa is one of the most common Gram-negative bacteria causing HAIs in hospitalized patients (10).

The World Health Organization (WHO) has placed carbapenem-resistant P. aeruginosa among critical priority pathogens that desperately requires new treatment options (11). Increasing rates of multidrug-resistant (MDR) P. aeruginosa in HAIs and among hospitalized patients is a major public health problem (12). Multidrug-resistant P. aeruginosa infections in the hospital setting are associated with poor outcomes including increased resource utilization and costs, morbidity, and mortality (10). In the USA, MDR P. aeruginosa accounts for 13–19% of the annual HAI burden. The increasing level of resistance in MDR P. aeruginosa is often attributed to patient-to-patient transmission of resistant strains, increasing rate of environmental colonization, as well as newly acquired resistance owing to previous antibiotic exposure (13).

In the management of severe systemic infections, multidrug-resistant P. aeruginosa must be part of the consideration when selecting empirical treatment to ensure timely and appropriate initial therapy. Instead of universal broad-spectrum antibiotics, specific antibiotic regimens should be determined using a more scientific approach. Such an approach should include acquiring site-specific diagnosis such as previous blood culture information to predict probable causative organisms based on epidemiological and host risk factors including recent infection exposures, evidence of colonization, indwelling devices, comorbidity, recent infections, recent antibiotic exposure in the preceding 3 months and host immunologic status (4).

Initiation of antibiotics such as ceftriaxone and amoxicillin-clavulanic acid with no P. aeruginosa coverage often leads to inappropriate initial therapy that adversely impacts health outcomes (14). This study aimed to determine the rate of inappropriate empirical therapy in patients with P. aeruginosa infections at the University of Benin Teaching Hospital, Nigeria.

Materials and method:

Study setting, period and design:
The study was conducted at the University of Benin Teaching Hospital, Edo State, Nigeria between January and December 2022. This was a retrospective cross-sectional study involving the review of the clinical consults sent to consultant clinical microbiologists at the University of Benin Teaching Hospital for a period of one year.

Study procedure and data collection:
The clinical consults were analyzed for the following parameters; initial diagnosis, reasons for the invitation, and empirical antibiotics administered. Isolates and the in vitro susceptibility profile of the initial samples sent for microbiology profile before or immediately after initiating antibiotics were also included in the analysis. Samples that yielded growth of P. aeruginosa were included for further evaluations to determine the extent the in-vitro susceptibility profiles differ (discordant empirical antibiotic therapy) or aligned with the initial empiric antibiotics prescribed. In cases where multiple samples from one patient grew P. aeruginosa, only one isolate was included.

Clinical samples included in the study were blood culture, urine, body fluid aspirates and wound swabs. Empirical antibiotic therapy was considered discordant (DEAT) if P. aeruginosa isolate did not display in vitro susceptibility to any systemic antibiotic administered shortly before or immediately after sample collection. Pan-resistant isolate was defined as resistance to all antibiotics tested (15).

Results:

Of the 256 consults received during the study period, all but two patients were on antibiotics before review, giving antibiotic prevalence rate of 99.2%. Pseudomonas aeruginosa was isolated from 57 (22.3%) patients as pathogens. Of this, only 14 (24.6%) received at least one anti-pseudomonas antibiotics which puts the total discordant rate at 75.4% (Fig 1).

The ICU had the highest number of P. aeruginosa infected patients closely followed by the surgical ward at 18 (31.6%) and 15 (26.3%) respectively. The percentage of DEAT was 66.7% each for ICU and Paediatrics wards (Table 1). Metronidazole (22.7%) and ceftriaxone-sulbactam (Tandak) (21.5%) were the most commonly prescribed empirical antibiotics (Fig 3) while the most common reasons for consultation were the diagnosis of sepsis, followed by pan-resistant isolates respectively at 40.2% and 34.8% (Fig 4). The distribution of P. aeruginosa by specimen sources shows that urine had the highest yield of the studied pathogens followed by wound swabs at 43.9% and 29.8% respectively (Fig 4).
Discordant empirical antibiotic therapy of Pseudomonas aeruginosa infection


Fig 1 Frequency of *Pseudomonas aeruginosa* isolate and anti-pseudomonas prescribed

Fig 2: Patterns of empirical antibiotics prescribed before or after sample collection
Discordant empirical antibiotic therapy of Pseudomonas aeruginosa infection

**Fig 3:** Frequency (%) of consults by reason for request

**Table 1:** Distribution of *Pseudomonas aeruginosa* infection by ward and discordant empirical antibiotic therapy

<table>
<thead>
<tr>
<th>Ward/units</th>
<th>No of patients with <em>Pseudomonas aeruginosa</em> infection (%)</th>
<th>No on anti-<em>Pseudomonas aeruginosa</em> coverage (%)</th>
<th>No of DEAT (%)</th>
<th>$x^2$</th>
<th>$p$ value</th>
</tr>
</thead>
<tbody>
<tr>
<td>ICU</td>
<td>18 (31.6)</td>
<td>6 (33.3)</td>
<td>12 (66.7)</td>
<td>1.806</td>
<td>0.7714</td>
</tr>
<tr>
<td>Surgical ward</td>
<td>15 (26.3)</td>
<td>3 (20.0)</td>
<td>12 (80.0)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>O&amp;G</td>
<td>7 (12.3)</td>
<td>1 (14.3)</td>
<td>6 (85.7)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Medicine</td>
<td>11 (19.3)</td>
<td>2 (18.2)</td>
<td>9 (81.8)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Paediatrics ward</td>
<td>6 (10.5)</td>
<td>2 (33.3)</td>
<td>4 (66.7)</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>57</strong></td>
<td><strong>14 (24.6)</strong></td>
<td><strong>43 (75.4)</strong></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

DEAT = Discordant empirical antibiotic therapy; ICU=Intensive Care Unit
Discordant empirical antibiotic therapy of Pseudomonas aeruginosa infection


Discussion:

Timely administration of effective antibiotic therapy is associated with improved outcomes in patients with severe infections such as sepsis and bloodstream infections (9). However, the uncompromisable lag between sampling of cultures and the availability of in vitro susceptibility report make empirical antibiotic selection challenging especially when infection involves pathogen such as P. aeruginosa which besides being intrinsically resistant to a number of common antibiotics, are known to possess various mechanism of resistance to different classes of antibiotics (4,9). The key predictors of discordant empirical antimicrobial therapy which include antibiotic-resistant phenotype such as P. aeruginosa and high antimicrobial resistance prevalence setting (16) are common features seen in this study. As demonstrated by various studies, there is high degree antibiotics resistance from isolates obtained from clinical samples in Nigerian’s hospitals (17).

In this study, the discordant empirical antimicrobial therapy rate was 75.4%. This is much higher than findings from other studies (16) probably because our study was done in a setting with high prevalence of resistance to antibiotics and the focus was on a notable resistant pathogen. Also, the studies with low DEAT rate besides the low resistant prevalence setting were focused on only blood stream infections (9,16). Empirical antibiotics reported as the most administered in the study were ceftriaxone-sulbactam (Tandak) and metronidazole. Although this combination is broad spectrum sufficient to cover most Gram-positive, Gram-negative and anaerobic organisms, it does not have sufficient coverage for P. aeruginosa (18). This pattern of prescription was similar to a report by Abubakar et al., (19) and other studies (20,21) which reported metronidazole and ceftriaxone as the most administered antibiotics among patients admitted to tertiary healthcare. The need for a broad-spectrum antibiotic therapy may have informed the general choice of ceftriaxone and metronidazole as among the common empirical antibiotics across most studies, even if it lacks potency for most pathogens with resistant encoding genes.

Sepsis closely followed by pan-resistant isolates were the common reasons for referrals to the clinical microbiologists, which accounted for 40.2% and 34.8% respectively. This is likely due to the understanding that the management of sepsis involves multidisciplinary approach and also clinical microbiologists largely play the roles of infectious diseases physician in our settings (22). In the analysis of the distribution of P. aeruginosa by ward/unit, it somewhat showed direct correlations with HAI, with ICU having the highest recovery of P. aeruginosa at the rate of 31.6%. This could be explained by the fact that ICU admission is a strong determinant of HAI, and P. aeruginosa is a prominent pathogen in this category of infection (23).

Pseudomonas aeruginosa is a notable pathogen for serious infection especially in the immunocompromised hosts including those with severe burn, surgical site infection and those with indwelling devices such as urethral catheter (24). In this study, the highest number of P. aeruginosa were isolated from urine (42.9%) followed by wound swabs (29.8%). A similar observation was reported in another study with urine also the highest source for this pathogen (24,25). The high

Fig 4: Frequency of Pseudomonas aeruginosa isolates by specimen types
yield of *P. aeruginosa* from the urine samples in our study may be due the fact that most of the patients were in patient who have stayed more 48 hours on admission, and many of whom would have been on urethral catheter or other devices which usually encourage biofilm formation by this organism (26).

Our study has some limitations. First, the study findings were based only on sample of patients whose consults were sent to the clinical microbiologists, which might not necessarily be the true picture, and secondly, some of the cases reviewed had no sample collected for culture before clinical microbiologist’s review. These were excluded and could have further reduced the number of *P. aeruginosa* in the study

**Conclusion:**

In general, the routine antibiotics prescribed on the empirical basis in our setting are broad spectrum, however, they lack coverage for the common multi-drug resistant pathogens associated with HAIs such as *P. aeruginosa*. As a result, the unintended use of these antibiotic regimens often results in inappropriate initial therapy that adversely impacts health outcomes.

**Contributions of authors:**

IJA conceptualized and designed the study, conducted the analysis and wrote the first draft. LPVO reviewed the manuscript. The authors read and approved the final manuscript

**Source of funding:**

No funding was received for the study.

**Conflict of interest:**

No conflict of interest is declared.

**References:**


Discordant empirical antibiotic therapy of Pseudomonas aeruginosa infection


